The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

Colorectal Disease

Volumn 10, Issue 7, 2008, Pages 663-667

  Canna, K ^a   Hilmy, M ^a   Mcmillan, Donald C ^a   Smith, G W ^b   Mckee, R F ^a   Mcardle, C S ^a   Mcnicol, A M ^b  

^a University Department of Surgery   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

C reactive protein; Colorectal cancer; Dukes stage; Ki 67; Survival

Indexed keywords

C REACTIVE PROTEIN; FLUOROURACIL; KI 67 ANTIGEN;

AGE; AGED; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR GROWTH;

AGED; C-REACTIVE PROTEIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 50349093208     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2007.01416.x     Document Type: Article

References (29)

1. Cancerstats, 2004. http://www.cancerresearchuk.org (accessed May 2007).
2. McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer 2002; 86: 331-5.
3. Rosenwald IB. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 2004; 23: 3230-47.
4. Brown DC, Gatter KC. Ki67 protein: The immaculate deception? Histopathology 2002; 40: 2-11.
5. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77: 255-64.
6. Kyzer S, Gordon PH. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67. Dis Colon Rectum 1997; 40: 322-5.
7. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998; 28: 971-9.
8. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R. Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes'stage B colorectal cancers. Br J Cancer 1999; 79: 577-81.
9. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T. Expression of cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84: 225-33.
10. Nanashima A, Yamaguchi H, Shibasaki S, Sawai T, Yasutake T, Tsuji T, Nakagoe T, Ayabe H. Proliferation of hepatic metastases of colorectal carcinoma: Relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 1999; 14: 61-6.
11. Mairinger T, Happacher R, Gabl C, Hoffmann Y, Ofner D, Schmid KW, Gschwendtner A. Mean weighted nuclear volumes in colonic adenocarcinomas. Evaluation of prognostic significance. Anal Quant Cytol Histol 1999; 21: 194-200.
12. Kubota Y, Petras RE, Easley KA, Bauer TW, Tubbs RR, Fazio VW. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992; 70: 2602-9.
13. Jansson A, Sun XF. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 1997; 105: 730-4.
14. Buglioni S, D'Agnano I, Cosimelli M, Vasselli S, D'Angelo C, Tedesco M, Zupi G, Mottolese M. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas independent prognostic role of p53 and bcl-2. Int J Cancer 1999; 84: 545-52.
15. Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F, Kohno N. Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 2000; 16: 55-64.
16. Ofner D, Grothaus A, Riedmann B, Larcher P, Maier H, Bankfalvi A, Schmid KW. MIB1 in colorectal carcinomas: Its evaluation by three different methods reveals lack of prognostic significance. Anal Cell Pathol 1996; 12: 61-70.
17. Valera V, Yokoyama N, Walter B, Okamoto H, Suda T, Hatakeyama K. Clinical significance of Ki-67 proliferation index in disease progression and prognosis of patients with resected colorectal carcinoma. Br J Surg 2005; 92: 1002-7.
18. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2002; 7: 617-23.
19. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-9.
20. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004; 90: 1707-9.
21. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. Br J Cancer 1958; 12: 309-20.
22. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 2000; 37: 36-40.
23. Shepherd NA, Richman PI, England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol 1988; 155: 213-9.
24. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92: 651-4.
25. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001; 357: 539-45.
26. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-8.
27. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
28. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-31.
29. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, McMillan DC. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer 2006; 94: 1833-6.